Monograph Details
|
|
Endocrine System
> Diabetes
|
|
COZAAR |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker. |
| Generic Name |
|
Losartan potassium 25mg, 50mg, 100mg; tabs. |
| Indications |
|
Treatment of diabetic nephropathy in type 2 diabetes with hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
Initially 50mg once daily; may increase to 100mg once daily. |
| Contraindications |
|
Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct salt/volume depletion before starting therapy, or reduce initial dose. Renal or hepatic impairment. Severe CHF. Renal artery stenosis. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Antihypertensive effect reduced by NSAIDs. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. Monitor lithium. |
| Adverse Reactions |
|
Dizziness, insomnia, muscle cramps, leg pain, hyperkalemia, angioedema, orthostatic hypotension, rhabdomyolysis (rare). |
| How Supplied |
Tabs 25mg—90, 1000, 10000
50mg—30, 90, 1000, 10000
100mg—30, 90, 1000, 5000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
